https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development...
/PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment...
https://www.fiercebiotech.com/biotech/novos-injectable-amycretin-yet-hit-weight-loss-plateau-suggesting-zepbound-beating?ref=morpheus-research.com
Novo's injectable amycretin yet to hit weight loss plateau
Jun 23, 2025 - The results suggest the Danish drugmaker's upcoming phase 3 program can improve on the data that triggered a jump in its share price early this year.
weight lossnovoinjectableamycretinyet
https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/02/14/43/Oral-Subcutaneous-Amycretin?ref=morpheus-research.com
Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 Monoagonists - American College of...
https://www.biospace.com/press-releases/novo-nordisk-successfully-completes-phase-1b-2a-trial-with-subcutaneous-amycretin-in-people-with-overweight-or-obesity
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with...